Please assess the completion status of the following clinical trial:

Trial Title: Pediatric Concussion Outcomes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~In order to be eligible to participate in this study, an individual must meet all of the following criteria:~1. Provision of signed and dated informed consent form~2. Stated willingness to comply with all study procedures and availability for the duration of the study~3. Participants aged 13-21 years old~4. In good general health as evidenced by medical history and diagnosed with recent head trauma meeting ICHD-3 criteria for acute posttraumatic headache with symptom onset \< 7 days from trauma~5. Ability to take oral medication and be willing to adhere to the medication regimen~6. No loss of consciousness OR loss of consciousness \<30 minutes~7. Headache symptoms persisting ≥4 weeks post trauma~8. PCSHE score for headache + pressure in head + neck pain must be \> 3~9. After week 4 post-concussion at time of enrollment~10. Not currently receiving pharmacologic treatment for concussion asid from NSAIDs and acetaminophen~Exclusion Criteria:~An individual who meets any of the following criteria will be excluded from participation in this study:~1. Focal neurological deficits following injury~2. Any acute abnormality on Computed Tomography (if obtained)~3. History of known seizure disorder or moderate or severe TBI~4. Current uncontrolled psychiatric illness given the potential side effects of the study drug (at investigator discretion).~5. Current suicidal ideation as screened for on PHQ on intake~6. A personal history of Brugada syndrome~7. Known allergic reaction to nortriptyline~8. Current pregnancy~9. Positive COVID-19 test in prior 14 days

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 21 Years
- Healthy Volunteers: t

Study Arms:
- Experimental (Type: EXPERIMENTAL): 10mg capsule once daily for 4 weeks of nortriptyline
- Control (Type: PLACEBO_COMPARATOR): 10mg capsule once daily for 4 weeks of Thick-It filler

Based on this trial design, predict the completion outcome and termination type (if applicable).